Posted by Michael Wonder on 25 Sep 2021
CARISMA Therapeutics announces U.S. FDA grants fast track designation to CT-0508 for the treatment of patients with solid tumours
22 September 2021 - CARISMA Therapeutics announced today that that the U.S. FDA has granted fast track designation to CT-0508, a human epidermal growth factor receptor 2 targeted chimeric antigen receptor macrophage for the treatment of patients with solid tumours.
CT-0508 was originally developed by Saar Gill, Scientific Co-founder of CARISMA Therapeutics, and an Associate Professor of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania, and Michael Klichinsky, Scientific Co-founder, and Senior Vice President of Discovery at CARISMA Therapeutics.
